h1

h2

h3

h4

h5
h6

001     797620
005     20230209042754.0
024 7 _ |a G:(EU-Grant)847949
|d 847949
|2 CORDIS
024 7 _ |a G:(EU-Call)H2020-SC1-2019-Two-Stage-RTD
|d H2020-SC1-2019-Two-Stage-RTD
|2 CORDIS
024 7 _ |a corda__h2020::847949
|2 originalID
035 _ _ |a G:(EU-Grant)847949
150 _ _ |a DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES
|y 2020-04-01 - 2025-09-30
371 _ _ |a FUNDACION PUBLICA MIGUEL SERVET
|b FMS
|d Spain
|e http://www.navarrabiomed.es
|v CORDIS
371 _ _ |a EUROPEAN ASSOCIATION FOR THE STUDYOF THE LIVER
|b EUROPAISCHE VEREINIGUNG FUR LEBERFORSCHUNG EASL
|d Switzerland
|e http://www.easl.eu
|v CORDIS
371 _ _ |a EUROPEAN LIVER PATIENTS ASSOCIATION
|b ELPA
|d Belgium
|e http://www.elpa.eu
|v CORDIS
371 _ _ |a University of London - University College London
|b UCL
|d United Kingdom
|e http://www.ucl.ac.uk/
|v CORDIS
371 _ _ |a IT Consult
|b IT Consult
|d Germany
|e http://www.itconsult-eu.de/
|v CORDIS
371 _ _ |a Atomic Energy and Alternative Energies Commission
|b CEA
|d France
|e http://www.cea.fr/
|v CORDIS
371 _ _ |a University of Turin
|b UNITO
|d Italy
|e http://en.unito.it/
|v CORDIS
371 _ _ |a ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
|b ERASMUS MC
|d Netherlands
|e http://www.erasmusmc.nl
|v CORDIS
371 _ _ |a Nordic Bioscience (Denmark)
|b Nordic Bioscience (Denmark)
|d Denmark
|v CORDIS
371 _ _ |a University of Padua
|b UNIPD
|d Italy
|e http://www.unipd.it/en/home-page
|v CORDIS
371 _ _ |a Inserm
|b INSERM
|d France
|e http://english.inserm.fr/
|v CORDIS
371 _ _ |a Fundació Clínic per a la Recerca Biomèdica
|b Fundació Clínic per a la Recerca Biomèdica
|d Spain
|v CORDIS
371 _ _ |a Autonomous University of Barcelona
|b UAB
|d Spain
|e http://www.uab.cat/web/universitat-autonoma-de-barcelona-1345467954774.html
|v CORDIS
371 _ _ |a INSTITUT CATALA DE LA SALUT
|b ICS
|d Spain
|v CORDIS
371 _ _ |a Universitätsklinikum Aachen
|b UKA
|d Germany
|e http://www.ukaachen.de/
|v CORDIS
371 _ _ |a University of Bologna
|b UNIBO
|d Italy
|e http://www.unibo.it/en/homepage
|v CORDIS
371 _ _ |a YH YOUHEALTH AB
|b YH
|d Sweden
|e http://www.youhealth.se
|v CORDIS
371 _ _ |a SERVICIO MADRILENO DE SALUD
|b SERMAS
|d Spain
|e http://cort.as/10Yf
|v CORDIS
371 _ _ |a Johann Wolfgang Goethe-Universtität Fachbereich Informatik und Mathematik Institut für Mathematik
|b GUF
|d Germany
|e http://www.uni-frankfurt.de/
|v CORDIS
371 _ _ |a Assistance Publique -Hopitaux De Paris
|b AP-HP
|d France
|e http://www.aphp.fr/
|v CORDIS
371 _ _ |a European Foundation for the Study of Chronic Liver Failure
|b EF CLIF
|d Spain
|e http://www.efclif.com/
|v CORDIS
372 _ _ |a H2020-SC1-2019-Two-Stage-RTD
|s 2020-04-01
|t 2025-09-30
450 _ _ |a DECISION
|w d
|y 2020-04-01 - 2025-09-30
510 1 _ |0 I:(DE-588b)5098525-5
|a European Union
|2 CORDIS
680 _ _ |a In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. This mortality is mainly due to cirrhosis decompensation, i.e. development of ascites, hepatic encephalopathy, and/or gastrointestinal hemorrhage, and its progression to acute-on-chronic liver failure (ACLF). Patients with decompensated cirrhosis receive many treatments such as intravenous and oral absorbable antibiotics, oral non-absorbable antibiotics, albumin, proton-pump inhibitors, laxatives, diuretics, betablockers, vasoconstrictors, statins, anticoagulants, steroids and antiviral agents. Despite these multiple treatments, ACLF or mortality in patients with decompensation of cirrhosis remains high (15% at day 28, 28% at day 90) because of large interindividual variability in precipitating events, in clinical presentation and in response to treatment. This heterogeneity calls for treatment personalization according to underlying mechanisms. The objective of DECISION is to enhance our understanding, at systems level, of the pathophysiology of decompensation of cirrhosis leading to ACLF or death to decrease patients’ mortality at day 28. First, DECISION will improve our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from 2,200 fully characterized patients (more than 8,600 time points) with available standardized biological samples. Second, we will identify novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. We will refine these therapies in new and/or optimized animal models and then test the best combination in high risk patients in a phase II clinical trial built in DECISION. Third, we will develop 2 tests: one predicting outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test); and the other identifying patients who will respond to the novel combinatorial therapy (test for response).
909 C O |o oai:juser.fz-juelich.de:880067
|p authority:GRANT
|p authority
909 C O |o oai:juser.fz-juelich.de:880067
970 _ _ |a oai:dnet:corda__h2020::2d52f73ec2f2ca9c1c20639e772dfc55
980 _ _ |a G
980 _ _ |a CORDIS
980 _ _ |a AUTHORITY

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21